Please assess the completion status of the following clinical trial:

Trial Title: Effect of Infusion of Lidocaine, Magnesium and Remifentanil Perioperatively in Patients Undergoing Mastectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients scheduled for elective surgery performed mastectomy;~* Physical Status P1 and P2 of the American Society of Anesthesiology (ASA);~Exclusion Criteria:~* Patients with less than 18 years and above 75 years of age;~* Patients who are allergic to morphine and / or lidocaine and / or remifentanil and / or magnesium sulphate;~* Patients with chronic pain;~* Patients with severe hepatic disease;~* Patients with severe renal disease;~* Patients with neurological disorders;~* Patients included in other clinical currently or within the past three months under general anesthesia studies;~* Patients who refuse to participate in the study;~* Any other condition that in the opinion of the investigator, may pose a risk to the patient or interfere with the study objectives;

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Remifentanil group (Type: ACTIVE_COMPARATOR): Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
- Lidocaine group (Type: ACTIVE_COMPARATOR): Patients in lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
- Magnesium group (Type: ACTIVE_COMPARATOR): Patients in lidocaine group received an intravenous bolus injection of 50 mg/kg magnesium sulphate followed by a continuous magnesium sulphate infusion of 15 mg/kg/hr.
- Magnesium and Lidocaine group (Type: ACTIVE_COMPARATOR): Patients received an intravenous bolus injection of 2 mg/kg lidocaine plus 50 mg/kg magnesium sulphate followed by a continuous lidocaine infusion of 3 mg/kg/hr plus 15 mg/kg/hr magnesium sulphate

Based on this trial design, predict the completion outcome and termination type (if applicable).